Mechanisms of Fingolimods Efficacy and Adverse Effects in Multiple Sclerosis
Ann Neurol 69:759-777, Cohen, J.A. & Chun, J., 2011
A Case of Hashimoto Encephalopathy Clinical Manifestation, Imaging, Pathology, Treatment, and Prognosis
The Neurologist 17:141-143, Zhao, W.,et al, 2011
Transition to Adult Care for Children with Chronic Neurological Disorders
Ann Neurol 69:437-444, Camfiled, P. & Camfield, C., 2011
Immune Reconstitution Inflammatory Syndrome in Patients With Multiple Sclerosis Following Cessation of Natalizumab Therapy
Arch Neurol 68:186-191, Miravalle,A.,et al, 2011
Phase III Dose-Comparison Study of Glatiramer Acetate for Multiple Sclerosis
Ann Neurol 69:75-82, Comi,G.,et al, 2011
Classification of Primary Progressive Aphasia and Its Variants
Neurol 76:1009-1014, Gorno-Tempini,M.L.,et al, 2011
The Evaluation of Rapidly Progressive Dementia
The Neurologist 17:67-74, Rosenbloom,M.H. &Atri,A., 2011
Prior Suggestive Symptoms in One-Third of Patients Consulting for a "First" Demyelinating Event
JNNP 82:323-325, Gout,O.,et al, 2011
Asymptomatic Spinal Cord Lesions Predict Disease Progression in Radiologically Isolated Syndrome
Neurol 76:686-692, 680, Okuda,D.T.,et al, 2011
Balos Concentric Sclerosis
NEJM 365:742, Wengert, O.,et al, 2011
Cost-effectiveness of disease-modifying therapy for multiple sclerosis
Neurol 77:355-363, Noyes, K.,et al, 2011
Frontal Headache
JAMA 306:317-318, Chang,H.J.,et al, 2011
Cardiac abnormalities in a follow-up study on carriers of Duchenne and Becker muscular dystrophy
Neurol 77:62-66, Schade van Westrum, S.M.,et al, 2011
Primary Central Nervous System Lymphoma in a Patient Treated with Natalizumab
Ann Neurol 69:1060-1062, Phan-Ba, R.,et al, 2011
A Dramatic Case of Intraventricular Cysticercosis
Arch Neurol 6:828-829, Cardenas, G.,et al, 2011
Diffusion-weighted MRI hyperintensity patterns differentiate CJD from other rapid dementias
Neurol 76:1711-1719, Vitali, P.,et al, 2011
Oral vs Intratympanic Corticosteroid Therapy for Idiopathic Sudden Sensorineural Hearing Loss
JAMA 305(20):2071-2079,2114, Rauch, S.D.,et al, 2011
Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis
Neurol 76:1858-1865, OConnor, P.W.,et al, 2011
Cortical Restricted Diffusion as the Predominant MRI Finding in Sporadic Creutzfeldt-Jakob Disease
Acta Radiologica 52:336-339, Talbott,S.D.,et al, 2011
Autoimmune Encephalopathy
Semin Neurol 31:144-157, Flanagan, E.,et al, 2011
LMNA Cardiomyopathy:Cell Biology and Genetics Meet Clinical Medicine
Disease Models & Mechanisms 4:562-568, Lu,J.T., et al, 2011
Myoglobinuria and Muscle Pain are Common in Patients With Limb-Girdle Muscular Dystrophy 21
Neurol 76:194-195, Mathews,K.D.,et al, 2011
MRI Only Conversion to Multiple Sclerosis Following a Clinically Isolated Syndrome
JNNP 82:176-179, Chard,D.T.,et al, 2011
Rapidly Progressive Corticobasal Degeneration Syndrome
Case Rep Neurol 3:185-190, Herrero Valverde, A.,et al, 2011
Hashimotos Encephalopathy
Radiol Case Reports 6:445-449, Ramalho, J. & Castillo, M., 2011
Clinical and Genetic Spectrum of Mitochondrial Neurogastrointestinal Encephalomyopathy
Brain 134:3326-3332, Garone, C.,et al, 2011
Isolated Bilateral Trigeminal Neuropathy in Sarcoidosis Presenting with Neurotrophic Corneal Ulcers
Ophthalmology & Eye Diseases 2:69-73, Gupta, M.,et al, 2010
Brainstem Lesion in Clinically Isolated Syndromes
Neurol 75:1933-1938, Tintore,M.,et al, 2010
Pregnancy and Fetal Outcomes After Interferon-b Exposure in Multiple Sclerosis
Neurol 75:1794-1802, Amato,M.P.,et al, 2010
Evidence for Acute Neurotoxicity After Chemotherapy
Ann Neurol 68:806-815, Petzold,A.,et al, 2010
Dysexecutive Syndrome: Diagnostic Criteria and Validation Study
Ann Neurol 68:855-864, Godefroy,O.,et al, 2010
Atypical Dementia
Lancet 376:656, Cohen-Bittan,J. et al, 2010
Clinical Features of Facioscapulohumeral Muscular Dystrophy 2
Neurol 75:1548-1554, Greef,J.C.,et al, 2010
New Aspects on Patients Affected by Dysferlin Deficient Muscular Dystrophy
JNNP 81:946-953, Klinge,L.,et al, 2010
Clinical and Neuroimaging Findings of Cree Leukodystrophy: A Retrospective Case Series
AJNR 31: 1418-1423, Harder,S.,et al, 2010
Safety and Efficacy of Natalizumab in Children With Multiple Sclerosis
Neurol 75:912-917, Ghezzi,A.,et al, 2010
Longitudinal Study of Vision and Retinal Nerve Fiber Layer Thickness in Multiple Sclerosis
Ann Neurol 67:749-760, Talman,L.S., et al, 2010
Cardiotoxicity and Other Adverse Events Associated With Mitoxantrone Treatment for MS
Neurol 74:1822-1826, Kingwell,E., et al, 2010
Neurosacrcoidosis: Presentations and Management
Neurologist 16:2-15, Terushkin,V.,et al, 2010
Delirious Deficiency
Lancet 376:1362, Olsen,R.Q &Regis,J.T., 2010
Sudden Sensorineural Hearing Loss
The Lancet 375:1203-1211, Schreiber,B.E., et al, 2010
Treatment of Refractory Neurosarcoidosis with Infliximab
JNNP 81:241-246, Santos,E., et al, 2010
A Case of Neurosarcoidosis Successfully Treated with Rituximab
Neurol 75:568-570, Bomprezzi,R., et al, 2010
Redefining Dysferlinopathy Phenotypes Based on Clinical Findings and Muscle Imaging Studies
Neurol 75:316-323,298, Paradas,C., et al, 2010
Rapid Disease Course in African Americans With Multiple Sclerosis
Neurol 75:217-223, Kister,I., et al, 2010
Critical Vasospasm During Fingolimod (FTY720) Treatment in a Patient With Multiple Sclerosis
Neurol 74:2022-2024, Schwarz,A., et al, 2010
Severe Cutaneous Candida Infection During Natalizumab Therapy in Multiple Sclerosis
Neurol 74:521-523, Gutwinski,S.,et al, 2010
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
NEJM 362:402-415, 456, Cohen,J.A.,et al, 2010
A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis
NEJM 362:416-426, 456, Giovannoni,G.,et al, 2010
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
NEJM 362:387-401, 456, Kappos, L.,et al, 2010